ONCT - Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary

Oncternal Therapeutics (ONCT) announces agreement with Lentigen Technology, a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.As part of the agreement, Lentigen will reserve capacity in 2021 to manufacture, test and release GMP lentivirus to support and accelerate the development of Oncternal’s CAR-T cell therapy program.Oncternal said that it is working on rapidly advancing its ROR1-targeting CAR-T cell immunotherapy program, and added that it aims to achieve first-in-human dosing of the program in the second half of 2021.Oncternal inked a research and development deal with Karolinska Institutet in Stockholm, Sweden, to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK ((Natural Killer)) cells from the laboratory into the clinic, the company had said earlier this month.Oncternal shares up ~2% premarket.

For further details see:

Oncternal inks manufacturing deal with Miltenyi Biotec subsidiary